Search clinical trials for: PF-06743649

Total 1296 results

Pfizer

Completed

A Study To Evaluate PF-05175157 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
University of Pennsylvania
Pfizer

Completed

Add On Treatment for Cognitive Deficits in Schizophrenia

Schizophrenia

United States
Pfizer

Completed

Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

Healthy

United States
Pfizer
Bristol-Myers Squibb

Completed

A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects

Healthy

Singapore, Belgium
Pfizer

Completed

Multiple Dose Healthy Volunteer Study of PF-03715455. (MD-MULTI DOSE)

Healthy Volunteers

Singapore
Taisho Pharmaceutical Co., Ltd.

Completed

A Study Of The Effect Of PF-04802540 On Sleep Measures

Healthy

United States
Pfizer

Completed

A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects

Pain

Belgium
Pfizer

Completed

A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects

Healthy

Singapore
Pfizer

Completed

A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers

Bipolar Depression

United States
Pfizer

Completed

A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Overweight

United States
Pfizer

Completed

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Hypercholesterolemia

United States
Pfizer

Completed

A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults

Healthy

Argentina
Pfizer

Completed

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Systemic Lupus Erythematosus

Spain, United States, Taiwan, Belgium, Czechia, Japan, Hungary, Germany, United Kingdom, China, France, Australia, Bulgaria, Hong Kong, Korea, Republic of, Colombia, Argentina, Canada, Greece, Italy, Mexico, Poland, Portugal, Romania, S... and more
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate... and other conditions

United States
Pfizer

Recruiting

A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function

Renal Impairment

United States
Pfizer

Completed

A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants.

Healthy

Belgium
Pfizer

Completed

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

Overweight and/or Obesity

Belgium
Shire

Completed

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease (OPERA)

Crohn's Disease

Korea, Republic of, United States, Spain, Japan, Serbia, Germany, Belgium, Netherlands, Poland, Austria, Bulgaria, Canada, France, Norway, Slovakia, South Africa
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteers

United States
Pfizer

Completed

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States, Belgium, Czechia, Slovakia
Pfizer

Completed

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, United States
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Attention Deficit Hyperactivity Disorder

United States
Pfizer

Completed

Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion

Healthy

Belgium
Pfizer

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers

Pain | Migraine Disorders

United States
Pfizer

Withdrawn

A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

Obesity
Pfizer

Completed

A Study Of PF-05175157 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Terminated

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

Healthy Volunteers

Belgium
Pfizer

Terminated

Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845

Healthy Volunteers

United States
Pfizer

Completed

CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

Carcinoma, Renal Cell
Pfizer

Completed

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Acne Inversa

United States, Australia, Canada
Sun Yat-sen University

Active, not recruiting

TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Pfizer

Completed

A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects (B538-05)

Healthy Subjects

United States
Guangdong Association of Clinical Trials

Not yet recruiting

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Carcinoma, Non-Small-Cell Lung | Brain Metastases | Leptomeningeal Metastasis

China
Pfizer

Active, not recruiting

A Study to Learn How Different Amounts and Forms of the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults

Healthy Participants

Belgium
Basilea Pharmaceutica

Active, not recruiting

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in People With Hepatic Dysfunction.

Hepatic Impairment

United States
Pfizer

Active, not recruiting

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

Ulcerative Colitis

United States, Poland, Germany
Pfizer

Completed

A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults

Healthy Participants

Belgium
Pfizer

Completed

A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers

Healthy

Belgium
Pfizer

Completed

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

SARS-CoV-2 Infection

United States
Pfizer

Completed

Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

Healthy

Japan
Pfizer

Completed

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

Rheumatoid Arthritis | Systemic Lupus Erythematosus

United States
Pfizer

Completed

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Grupo Espanol de trasplantes hematopoyeticos y...

Active, not recruiting

Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease

Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)

Spain
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Yale University

Completed

Cannabinoid Augmentation of Fear Response in Humans

Fear Conditioning

United States
Pfizer

Terminated

Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants

Healthy

Belgium
Biogen

Completed

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia (MAD)

Schizophrenia

United States

3

Subscribe